Advertisement

Topics

Search Results for "En Vivo EVP6124 Alzheimer"

09:49 EDT 24th June 2017 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear ...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

The effects of different familial Alzheimer’s disease mutations on APP processing in vivo

Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer’s disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may s...

Medical News Today: Five of the best Alzheimer's blogs

Alzheimer's-related blogs may help to support people with Alzheimer's disease and their caregivers. We take a look at five of the best Alzheimer's blogs.

Five million american seniors now living with alzheimer's

(HealthDay)—Alzheimer's disease claims nearly twice as many American lives annually as it did just 15 years ago, according to the 2017 Alzheimer's Disease Facts and Figures report, published March 7...

One Doctor's Hopeful Plan To Eradicate Alzheimer's

A new drug developed by Neurogeneticist Dr. Rudolph Tanzi could be part of a cure for Alzheimer's disease within the decade. Tanzi, who co-discovered all three early-onset familial Alzheimer’s genes...

New Drug That Could Help Eradicate Alzheimer's Is Ready For Trials

A new drug developed by Neurogeneticist Dr. Rudolph Tanzi could be part of a cure for Alzheimer's disease within the decade. Tanzi, who co-discovered all three early-onset familial Alzheimer’s genes...

Alzheimer's Association calls for new strategies against dementia in Scientific American

(Alzheimer's Association) The time has come for advancing combination therapies against Alzheimer's disease, explains James A. Hendrix, Ph.D., Alzheimer's Association director of global science initia...

Alzheimer's Staggering $259B Cost Could Break Medicare

The cost of providing care for Americans with Alzheimer’s disease has hit $259 billion – more than a quarter of a trillion dollars – a new report from the Alzheimer's Association.

Alzheimer's experts call for changes in FDA drug approval standards

(Amplify Public Affairs) Leading Alzheimer's disease researchers and a prominent patient advocate today published an analysis, 'Single Endpoint for New Drug Approvals for Alzheimer's Disease,' urging ...

Matching PubMed Articles

Association of In Vivo 18FAV-1451 Tau PET Imaging Results With Cortical Atrophy and Symptoms in Typical and Atypical Alzheimer Disease.

Previous postmortem studies have long demonstrated that neurofibrillary tangles made of hyperphosphorylated tau proteins are closely associated with Alzheimer disease clinical phenotype and neurodegen...

In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.

The clinical heterogeneity of Alzheimer's disease is not reflected in the rather diffuse cortical deposition of amyloid-β. We assessed the relationship between clinical symptoms, in vivo tau patholog...

The application of lipidomics to biomarker research and pathomechanisms in Alzheimer's disease.

Alzheimer's disease is the most common cause of dementia. There are still no disease modifying treatments that can cure or slow disease progression. Recently, Alzheimer's disease researchers have atte...

Perspective on calcium and Alzheimer disease.

Early and late change on the preclinical Alzheimer's cognitive composite in clinically normal older individuals with elevated β-amyloid.

Sensitive detection of cognitive decline over the course of preclinical Alzheimer's disease is critical as the field moves toward secondary prevention trials.

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement